Journal Home
Search for

Volume 86, Issue 3, Pages 193-198 (December 2009)


View previous. 6 of 21 View next.

MCP-1 gene A-2518G polymorphism and carotid artery atherosclerosis in patients with type 2 diabetes

Sachiko YuasaaCorresponding Author Informationemail address, Taro Maruyamab, Yukihiro Yamamotoa, Hiroshi Hirosea, Toshihide Kawaia, Seiko Matsunaga-Iriea, Hiroshi Itoha

Received 3 January 2009; received in revised form 19 August 2009; accepted 1 September 2009. published online 25 September 2009.

Abstract 

Aims

Cardiovascular diseases are the major cause of mortality in patients with diabetes mellitus. Monocyte chemoattractant protein-1 (MCP-1) is a potent chemokine and plays an important role in cardiovascular diseases. The objective of this study was to evaluate the relation between the genotypes of the MCP-1 A-2518G polymorphism and the development of carotid atherosclerosis in patients with type 2 diabetes.

Methods

The subjects were 303 unrelated patients who were diagnosed with type 2 diabetes mellitus. To evaluate macroangiopathy, we measured carotid artery intima-media thickness (IMT) by ultrasonography. The MCP-1 A-2518G polymorphism was determined by TaqMan PCR method.

Results

IMT in patients with the MCP-1 −2518 AG or GG genotype was significantly greater than the AA-genotype (P=0.007). Simple regression analysis showed that age, systolic blood pressure, LDL-cholesterol, the MCP-1 −2518 AG+GG polymorphism, and HbA1c level were correlated with IMT (P<0.0001, <0.0001, 0.006, 0.007, 0.025, respectively). In multiple regression analysis, the MCP-1 −2518 AG+GG polymorphism was the third strongest independent determinant of IMT in patients with type 2 diabetes (P=0.021), subsequent to age and systolic blood pressure.

Conclusion

Assessment of the MCP-1 A-2518G polymorphism would be useful in identifying the risk of developing carotid atherosclerosis in patients with type 2 diabetes.

a Division of Metabolism, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

b Department of Internal Medicine, Saitama Social Insurance Hospital, Saitama, Japan

Corresponding Author InformationCorresponding author. Tel.: +81 3 3353 1211x62383; fax: +81 3 5269 3219.

PII: S0168-8227(09)00372-6

doi:10.1016/j.diabres.2009.09.001


View previous. 6 of 21 View next.